New York State Teachers Retirement System Boosts Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

New York State Teachers Retirement System boosted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 43,764 shares of the biopharmaceutical company’s stock after purchasing an additional 837 shares during the period. New York State Teachers Retirement System’s holdings in TG Therapeutics were worth $1,317,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. State Street Corp grew its holdings in shares of TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after buying an additional 2,398,015 shares in the last quarter. Principal Financial Group Inc. grew its position in TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after buying an additional 725,371 shares in the last quarter. Castellan Group acquired a new stake in TG Therapeutics in the 4th quarter valued at about $8,539,000. Public Sector Pension Investment Board purchased a new stake in TG Therapeutics during the third quarter valued at about $6,619,000. Finally, JPMorgan Chase & Co. lifted its stake in TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock valued at $16,859,000 after buying an additional 270,286 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on TGTX. The Goldman Sachs Group increased their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. StockNews.com lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $40.67.

Insiders Place Their Bets

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.50% of the company’s stock.

TG Therapeutics Stock Down 0.2 %

Shares of NASDAQ TGTX opened at $30.88 on Monday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a one year low of $12.90 and a one year high of $36.84. The stock has a market capitalization of $4.81 billion, a PE ratio of -308.77 and a beta of 2.26. The business’s fifty day moving average price is $31.07 and its 200-day moving average price is $27.84.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.